Pancreatic Stone Protein Testing Market Size

  • Report ID: 4566
  • Published Date: Feb 15, 2023
  • Report Format: PDF, PPT

Pancreatic Stone Protein Testing Market Size

Pancreatic Stone Protein Market size is anticipated to cross USD 5 Billion by the end of 2033, witnessing around 3% CAGR during the forecast period, i.e., 2023-2033. In the year 2022, the industry size of pancreatic stone protein was USD 4 Billion. The growth of the market can be attributed to the globally rising prevalence of chronic diseases, caused by pancreatic stone formation. Some of these diseases include acute appendicitis, diabetes, gallstones, and optic atrophy, which is expected to drive the demand for global pancreatic stone protein testing market during the forecast period. It was observed that, in American Indians, gallstones are prevalent at a rate of about 55% to 65%, while the rate in white adults in developed countries is approximately 8% to 15%. Likewise, the rate of acute pancreatitis symptoms is higher in developing countries as well as in developed countries. For instance, the annual incidence of acute pancreatic in the U.S. ranges from 20 to 50 per 100,000 population.

The global pancreatic stone protein testing market size is expected to expand during the forecast period owing to its potential for detecting life-threatening diseases and monitoring the response to treatment. Additionally, the increasing cases of chronic & hereditary pancreatitis and pancreatic cancer worldwide are estimated to propel the growth of the global pancreatic stone protein testing market over the forecast period. According to the National Center for Biotechnology Information, a pancreatic cancer diagnosis is the seventh leading cause of cancer-related death in the world. There have been 458,918 new cases of pancreatic cancer recorded globally in 2018, and there are estimated to be 355,317 new cases occurring until the year 2040. Furthermore, assay techniques such as ELISA and immunoassay devices are some of the global pancreatic stone protein testing market trends expected to fuel the market growth during the forecast period.

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:

Author Credits:  Radhika Pawar

  • Report ID: 4566
  • Published Date: Feb 15, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing prevalence of diabetes globally along with rising demand for pancreatic stone protein testing as a biomarker are some of the major factors anticipated to drive the growth of the market.

The market is anticipated to attain a CAGR of 3% over the forecast period, i.e., 2023-2033.

High price associated with pancreatic stone protein testing and inaccuracy with PSP biomarkers are some of the factors estimated to hamper market growth.

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are RayBiotech Life, Inc., CUSABIO TECHNOLOGY LLC, LifeSpan BioSciences, Inc, Abbexa Limited, Boster Biological Technology CO LTD, Aviva Systems Biology Corporation, Glenmed Professional Healthcare Solutions., CREATIVE DIAGNOSTICS, Inc, Biomol GmbH, and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by technique, disease type, age group, end user, and by region.

The sepsis disease segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying